|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.42 CHF | -1.73% |
|
-2.14% | +11.70% |
| 07-14 | US FDA approves Celcuity's breast cancer drug | RE |
| 07-14 | Where would AI lead Pharma in the long run? |  |
| Market Cap | 277B 243B 225B 207B 390B 26,683B 398B 2,679B 1,049B 13,039B 1,042B 1,019B 44,998B | P/E 2026 * |
21.2x | P/E 2027 * | 17.9x |
|---|---|---|---|---|---|
| Enterprise Value | 309B 271B 250B 231B 435B 29,761B 444B 2,988B 1,170B 14,544B 1,162B 1,136B 50,190B | EV / Sales 2026 * |
5.44x | EV / Sales 2027 * | 5.08x |
| Free-Float |
91.66% | Yield 2026 * |
2.9% | Yield 2027 * | 3% |
Last Transcript: Novartis AG
| 1 day | -1.73% | ||
| 1 week | -2.14% | ||
| Current month | -3.29% | ||
| 1 month | +0.28% | ||
| 3 months | +1.49% | ||
| 6 months | +7.73% | ||
| Current year | +11.70% |
| 1 week | 122.02 |  | 126.52 |
| 1 month | 117.96 | | 128.92 |
| Current year | 107.68 | | 131 |
| 1 year | 91.2 | | 131 |
| 3 years | 81.1 | | 131 |
| 5 years | 72.84 | | 131 |
| 10 years | 65.09 | | 131 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-18 | Sell | -5,200 | 0.0003% | |||
| 05-04 | Sell | 6,800 | 0.0003% | |||
| 02-17 | Sell | 30,743 | 0.0015% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.73% | -2.14% | +27.22% | +44.70% | 281B | |
| -2.48% | -6.72% | +44.19% | +156.43% | 1,054B | |
| -1.52% | -5.01% | +61.87% | +58.79% | 621B | |
| -1.30% | -3.88% | +27.81% | +79.97% | 438B | |
| -1.12% | -1.45% | +27.34% | +22.20% | 325B | |
| -1.95% | -12.31% | +18.32% | +19.69% | 262B | |
| -1.45% | -0.44% | -27.17% | -38.86% | 219B | |
| -1.44% | -3.49% | +19.60% | +56.20% | 195B | |
| -1.04% | -4.63% | +16.01% | +68.47% | 163B | |
| -0.94% | +0.75% | -4.34% | -33.23% | 140B | |
| Average | -0.86% | -1.21% | +21.08% | +43.44% | 369.57B | |
| Weighted average by Cap. | -0.41% | -1.50% | +32.02% | +73.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 56.83B 49.76B 45.99B 42.43B 79.87B 5,466B 81.48B 549B 215B 2,671B 213B 209B 9,218B | 60.24B 52.75B 48.76B 44.98B 84.67B 5,795B 86.38B 582B 228B 2,832B 226B 221B 9,772B |
| Net income | 14.08B 12.33B 11.39B 10.51B 19.79B 1,354B 20.19B 136B 53.26B 662B 52.88B 51.71B 2,284B | 15.64B 13.7B 12.66B 11.68B 21.99B 1,505B 22.43B 151B 59.17B 735B 58.75B 57.45B 2,538B |
| Net Debt | 32B 28.02B 25.9B 23.9B 44.98B 3,078B 45.89B 309B 121B 1,504B 120B 118B 5,191B | 28.5B 24.96B 23.07B 21.28B 40.06B 2,742B 40.87B 275B 108B 1,340B 107B 105B 4,624B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/07/26 | CHF 122.42 | -1.73% | 2,431,098 |
| 13/07/26 | CHF 124.58 | +0.24% | 2,143,959 |
| 10/07/26 | CHF 124.28 | -0.02% | 2,334,841 |
| 09/07/26 | CHF 124.30 | -1.27% | 2,233,204 |
| 08/07/26 | CHF 125.90 | -0.71% | 2,243,169 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition